voltar
ACONTECE NA ABIFINA
Estudos sobre vacinas, drogas em desenvolvimento, drogas tradicionais, protocolos clínicos e suprimentos de IFAs para tratamento da Covid-19 (01/07/2020)
Acompanhe as atualizações!
O reposicionamento de fármacos como uma potencial estratégia para o tratamento da COVID-19
29.06.2020 - No final de 2019 uma nova cepa de coronavírus foi descoberta na China, responsável por causar a doença COVID-19, caracterizada pela OMS como uma pandemia em março de 2020
Combating COVID-19 with integrated traditional Chinese and Western medicine in China
June 27, 2020 - COVID-19, an acute respiratory infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread throughout the world
The role of angiotensin-converting enzyme 2 in the pathogenesis of COVID-19: the villain or the hero?
June 27, 2020 - Angiotensin-converting enzyme 2 (ACE 2) is the entry receptor for the novel coronavirus SARS-CoV-2, the aetiological agent of COVID-19
Successful recovery from COVID-19 pneumonia after receiving baricitinib, tocilizumab, and remdesivir. A case report: Review of treatments and clinical role of computed tomography analysis
June 27, 2020 - The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a pandemic, threatening global public health
Drug treatment of coronavirus disease 2019 (COVID-19) in Chin
June 27, 2020 - Since December 2019, the coronavirus disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has spread throughout China as well as other countries
Transcriptomic Signatures and Immunomodulatory Treatments for COVID-19 Patients
June 26, 2020 - Since December 2019, the novel coronavirus SARS-CoV-2 has infected over 9.0 million and led to death of over 472,000 people, damaging the world’s social and economic fabrics
SARS-CoV-2 Exoribonuclease (NSP14) As a Potential Therapeutic Target to Treat COVID-19
June 26, 2020 - Although the global health emergency caused by SARS-CoV-2 has led to unprecedented health and socioeconomic crisis, as of today neither an antiviral treatment has been approved for COVID-19, nor is a vaccine available
Glycans on the SARS-CoV-2 Spike Control the Receptor Binding Domain Conformation
June 26, 2020 - The glycan shield of the beta-coronavirus (β-CoV) Spike (S) glycoprotein provides protection from host immune responses, acting as a steric block to potentially neutralizing antibody responses
High-dose but not low-dose corticosteroids potentially delay viral shedding of patients with COVID-19
June 26, 2020 - Article PDF
Auxiliary role of mesenchymal stem cells as regenerative medicine soldiers to attenuate inflammatory processes of severe acute respiratory infections caused by COVID-19
June 25, 2020 - Acute respiratory infections as one of the most common problems of healthcare systems also can be considered as an important reason for worldwide morbidity and mortality from infectious diseases
Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection
June 24, 2020 - The Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly become a global pandemic
Tocilizumab in patients with severe COVID-19: a retrospective cohort study
June 24, 2020 - No therapy is approved for COVID-19 pneumonia. The aim of this study was to assess the role of tocilizumab in reducing the risk of invasive mechanical ventilation and death in patients with severe COVID-19 pneumonia who received standard of care treatment
In-hospital Use of Statins is Associated with a Reduced Risk of Mortality among Individuals with COVID-19
June 24, 2020 - Statins are lipid-lowering therapeutics with favorable anti-inflammatory profiles and have been proposed as an adjunct therapy for COVID-19. However, statins may increase the risk of SARS-CoV-2 viral entry by inducing ACE2 expression
Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies
June 23, 2020 - Neutralizing antibody responses to coronaviruses mainly target the receptor-binding domain (RBD) of the trimeric spike
Treatment of Coronavirus Disease 2019 (COVID-19): Investigational Drugs and Other Therapies
June 22, 2020 - Coronavirus disease 2019 (COVID-19) is defined as illness caused by a novel coronavirus now called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; formerly called 2019-nCoV), which was first identified amid an outbreak of respiratory illness cases in Wuhan City, Hubei Province, China
nCOV-19 peptides mass fingerprinting identification, binding, and blocking of inhibitors flavonoids and anthraquinone of Moringa oleifera and hydroxychloroquine
June 22, 2020 - An rare pandemic of viral pneumonia occurs in December 2019 in Wuhan, China, which is now recognized internationally as Corona Virus Disease 2019 (COVID-19), the etiological agent classified as Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2)
Constituents of buriti oil (Mauritia flexuosa L.) like inhibitors of the SARS-Coronavirus main peptidase: an investigation by docking and molecular dynamics
June 22, 2020 - Statistics show alarming numbers of infected and killed in the world, caused by the Covid-19 pandemic, which still doesn’t have a specific treatment and effective in combating all efforts to seek treatments and medications against this disease
Autophagy and SARS-CoV-2 infection: Apossible smart targeting of the autophagy pathway
June 22, 2020 - The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak resulted in 5,993,317 confirmed cases worldwide with 365,394 confirmed deaths (as of May 29 th , 2020, WHO)
Structure-based virtual screening and molecular dynamics simulation of SARS-CoV-2 Guanine-N7 methyltransferase (nsp14) for identifying antiviral inhibitors against COVID-19
June 22, 2020 - The recent pandemic caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) calls the whole world into a medical emergency
Promising inhibitors of main protease of novel corona virus to prevent the spread of COVID-19 using docking and molecular dynamics simulation
June 22, 2020 - Coronavirus disease-2019 (COVID-19) is a global health emergency and the matter of serious concern, which has been declared a pandemic by WHO
Current status of COVID-19 therapies and drug repositioning applications
June 19, 2020 - The rapid and global spread of a new human coronavirus (SARS-CoV-2) has produced an immediate urgency to discover promising targets for treatment of COVID-19
Convergent antibody responses to SARS-CoV-2 in convalescent individuals
June 18, 2020 - During the COVID-19 pandemic, SARS-CoV-2 infected millions of people and claimed hundreds of thousands of lives
Overview of therapeutic drug research for COVID-19 in China
June 17, 2020 - Since the outbreak of novel coronavirus pneumonia (COVID-19) in December 2019, more than 2,500,000 people worldwide have been diagnosed with SARS-CoV-2 as of April 22. In response to this epidemic, China has issued seven trial versions of diagnosis and treatment protocol for COVID-19
Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease
June 15, 2020 - A new coronavirus SARS-CoV-2, also called novel coronavirus 2019 (2019-nCoV), started to circulate among humans around December 2019, and it is now widespread as a global pandemic
The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis
June 14, 2020 - Coronavirus disease 2019, commonly known as COVID-19, is a raging global pandemic
Intracellular ABCB1 as a Possible Mechanism to Explain the Synergistic Effect of Hydroxychloroquine-Azithromycin Combination in COVID-19 Therapy
June 14, 2020 - The co-administration of hydroxychloroquine with azithromycin is proposed in COVID-19 therapy
Antiviral activity of the high-molecular-weight plant polysaccharides (Panavir(R))
June 14, 2020 - This short report is dedicated to the description of the wide antiviral and antibacterial activity of the immune-modulating agent Panavir(R)
Coronavirus breakthrough: dexamethasone is first drug shown to save lives
June 13, 2020 - In a large trial, a cheap and widely available steroid cut deaths by one-third among patients critically ill with COVID-19
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
June 13, 2020 - A vaccine to protect against COVID-19 is urgently needed. We aimed to assess the safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 (Ad5) vectored COVID-19 vaccine expressing the spike glycoprotein of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strain
Vaccination strategies to combat novel corona virus SARS-CoV-2
June 12, 2020 - The 2019-novel coronavirus disease (COVID-19) is caused by SARS-CoV-2 is transmitted from human to human has recently reported in China
Virtual screening, ADME/Tox predictions and the drug repurposing concept for future use of old drugs against the COVID-19
June 11, 2020 - The new Coronavirus (SARS-CoV-2) is the cause of a serious infection in the respiratory tract called COVID-19
Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: Insights from structures of protease and inhibitors
June 11, 2020 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), similar to SARS-CoV and the Middle East respiratory syndrome coronavirus (MERS-CoV), which belong to the same β-coronavirus group, induces sever acute respiratory disease, threatening human health
Prospects of Replication-Deficient Adenovirus Based Vaccine Development against SARS-CoV-2
June 10, 2020 - The current appearance of the new SARS coronavirus 2 (SARS-CoV-2) and it quickly spreading across the world poses a global health emergency
Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19)
June 10, 2020 - The ongoing Coronavirus Disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) signals an urgent need for an expansion in treatment options
Aminoglycosides can be a better choice over macrolides in COVID-19 regimen: Plausible mechanism for repurposing strategy
June 10, 2020 - In the current COVID-19 pandemic, prioritizing the immunity enhancers is equally important to anti-virals
Vacina nacional de Bio-Manguinhos/Fiocruz para novo coronavírus entrará em estudo pré-clínico
09.06.2020 - Vacina nacional de Bio-Manguinhos/Fiocruz para novo coronavírus entrará em estudo pré-clínico. Projeto está pronto para avançar em estudos in vivo
EMA receives application for conditional authorisation of first COVID-19 treatment in the EU
June 08, 2020 - EMA has now received an application for conditional marketing authorisation (CMA) of the antiviral medicine remdesivir for the treatment of COVID-19 and has formally started its evaluation
α-glucosidase inhibitors as host-directed antiviral agents with potential for the treatment of COVID-19
June 08, 2020 - The ongoing COVID-19 pandemic, caused by SARS-CoV-2, has pushed the health systems of many countries to breaking point and precipitated social distancing measures that have crippled economic activities across the globe
Monoclonal antibody as a potential anti-COVID-19
June 04, 2020 - Coronavirus disease 2019 (COVID-19) is expanding rapidly, which made it as one of top priorities for scientists to develop novel treatment strategies
Natural RNA dependent RNA polymerase inhibitors: Molecular docking studies of some biologically active alkaloids of Argemone mexicana
June 01, 2020 - COVID-19 has become disastrous for world and spread all over. Researchers all around the globe are working to discover a drug to cure from COVID-19
Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients
June 01, 2020 - Given the ongoing SARS-CoV-2 pandemic, identification of immunogenic targets against the coronavirus spike glycoprotein will provide crucial advances towards the development of sensitive diagnostic
Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2
May 29, 2020 - To date, no vaccines or effective drugs have been approved to prevent or treat COVID-19 and the current standard care relies on supportive treatments
Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019
May 27, 2020 - The efficacies of lopinavir-ritonavir or hydroxychloroquine remain to be determined in patients with coronavirus disease 2019 (COVID-19
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
May 27, 2020 - Remdesivir is an RNA polymerase inhibitor with potent antiviral activity in vitro and efficacy in animal models of coronavirus disease 2019 (Covid-19)
Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial
May 24, 2020 - Coronavirus disease 2019 (COVID-19), caused by a novel corinavirus (later named SARS-CoV-2 virus), was fistly reported in Wuhan, Hubei Province, China towards the end of 2019.
A human neutralizing antibody targets the receptor binding site of SARS-CoV-2
May 22, 2020 - An outbreak of the coronavirus disease 2019 (COVID-19)1–3, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)4 spread globally
Remdesivir for the Treatment of Covid-19 — Preliminary Report
May 22, 2020 - Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), none have yet been shown to be efficacious
Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis
May 22, 2020 - Often in combination with a second-generation macrolide, are being widely used for treatment of COVID-19, despite no conclusive evidence of their benefit
No Benefit for Lopinavir–Ritonavir in Severe COVID-19
May 21, 2020 - Treatment with the HIV combination drug lopinavir-ritonavir did not accelerate recovery or improve mortality rates among hospitalized patients with severe coronavirus disease 2019 (COVID-19), a trial in the New England Journal of Medicine reported.
Beximco Pharma introduces world’s first generic remdesivir for COVID-19 treatment
May 21, 2020 -Beximco Pharmaceuticals Limited (“Beximco Pharma”, “BPL” or “the Company”), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, announces the launch of remdesivir (under the brand name Bemsivir), an antiviral drug, which has been recently granted Emergency Use Authorization by the U.S. Food and Drug Administration for the treatment of COVID-19
Immunogenicity of a DNA vaccine candidate for COVID-19
May 20, 2020 - The coronavirus family member, SARS-CoV-2 has been identified as the causal agent for the pandemic viral pneumonia disease, COVID-19
Ministério da Saúde divulga diretrizes para tratamento medicamentoso de pacientes
20.05.2020 - As recomendações publicadas nesta quarta-feira (20) são para o tratamento precoce, com cloroquina e hidroxicloroquina, de pacientes com COVID-19, no Sistema Único da Saúde (SUS)
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
May 18, 2020 - SARS-CoV-2 is a newly emerged coronavirus responsible for the current COVID-19 pandemic that has resulted in more than 3.7 million infections and 260,000 deaths as of 6 May 2020
Proteomics of SARS-CoV-2-infected host cells reveals therapy targets
May 14, 2020 - A novel coronavirus was recently discovered and termed SARS-CoV-2. Human infection can cause coronavirus disease 2019 (COVID-19), which has been rapidly spreading around the globe1,2
JAK Inhibition as a New Treatment Strategy for Patients with COVID-19
May 11, 2020 - After the advent of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the outbreak of coronavirus disease 2019 (COVID-19) commenced across the world
An Update on Current Therapeutic Drugs Treating COVID-19
May 11, 2020 - The current pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has presented unprecedented challenges to the healthcare systems in almost every country around the world
Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State
May 11, 2020 - Among patients with coronavirus disease 2019 (COVID-19), is there an association between use of hydroxychloroquine, with or without azithromycin, and in-hospital mortality?
Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial
May 08, 2020 - Effective antiviral therapy is important for tackling the coronavirus disease 2019 (COVID-19) pandemic. We assessed the efficacy and safety of combined interferon beta-1b, lopinavir–ritonavir, and ribavirin for treating patients with COVID-19
Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment
May 01, 2020 - Today, the U.S. Food and Drug Administration issued an emergency use authorization for the investigational antiviral drug remdesivir for the treatment of suspected or laboratory-confirmed COVID-19 in adults and children hospitalized with severe disease
EMA starts rolling review of remdesivir for COVID-19
April 30, 2020 - EMA’s human medicines committee (CHMP) has started a ‘rolling review’ of data on the use of the investigational antiviral medicine remdesivir for the treatment of coronavirus disease (COVID-19)
Plataforma reúne gráficos interativos sobre a evolução da COVID-19 no Brasil
30.04.2020 - Os gráficos mostram a quantidade total de casos e óbitos confirmados, a incidência na população, a taxa de letalidade e o número de novos casos
Hopes rise for coronavirus drug remdesivir
April 29, 2020 - Despite conflicting studies, results from largest trial yet show the antiviral speeds up recovery, putting it on track to become a standard of care in the United States
Covid-19 Drugs & Vaccines Tracker
April, 2020 - In the months since the novel coronavirus rose from a regional crisis to a global threat, drug makers large and small have scrambled to advance their best ideas for thwarting a pandemic
COVID-19 Resource Centre
April 25, 2020 - To assist health workers and researchers working under challenging conditions to bring this outbreak to a close, The Lancet has created a Coronavirus Resource Centre. This resource brings together new 2019 novel coronavirus disease (COVID-19) content from across The Lancet journals as it is published. All of our COVID-19 content is free to access
Covid-19 Arrived in Seattle. Where It Went From There Stunned the Scientists
April 22, 2020 - As the coronavirus outbreak consumed the city of Wuhan in China, new cases of the virus began to spread out like sparks flung from a fire
Información técnica, precios y registros sanitarios de pruebas diagnósticas para detección del virus SARS-CoV-2 en 5 países de América Latina y otras regiones
Abil de 2020 - Información técnica, precios y registros sanitarios de pruebas diagnósticas para detección del virus SARS-CoV-2 en 5 países de América Latina y otras regiones
Exceptional GMP flexibilities for medicines manufacturers during the coronavirus (COVID-19) outbreak
April 22, 2020 - These temporary good manufacturing practice (GMP) flexibilities will be allowed to address the current exceptional circumstances
Connecting clusters of COVID-19: an epidemiological and serological investigation
April 21, 2020 - Elucidation of the chain of disease transmission and identification of the source of coronavirus disease 2019 (COVID-19) infections are crucial for effective disease containment
Coronavirus Infections May Not Be Uncommon, Tests Suggest
April 21, 2020 - Two preliminary efforts to survey citizens for antibodies to the virus have produced controversial results
Developing therapeutic monoclonal antibodies at pandemic pace
April 21, 2020 -The time from discovery to proof-of-concept trials could be reduced to 5–6 months from a traditional timeline of 10–12 months
Coronavirus (COVID-19) Update: FDA Authorizes First Test for Patient At-Home Sample Collection
April 21, 2020 - The U.S. Food and Drug Administration authorized the first diagnostic test with a home collection option for COVID-19
Launch of enhanced monitoring system for availability of medicines used for treating COVID-19
April 21, 2020 - EMA, together with the pharmaceutical industry and the EU Member States, has launched its enhanced fast-track monitoring system to help prevent and mitigate supply issues with crucial medicines used for treating patients with COVID-19
Update to guidance on regulatory expectations in the context of COVID-19 pandemic
April 20, 2020 - The European Commission, EMA and the national competent authorities have agreed a series of measures to mitigate the impact of disruptions caused by COVID-19 on the conduct0 of inspections of manufacturing facilities or other sites relevant for medicinal products in the European Union
Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status
April 19, 2020 - Coronaviruses are a large group of viruses known to cause illnesses that vary between the common cold and more severe diseases to include severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS)
NIH to launch public-private partnership to speed COVID-19 vaccine and treatment options
April 17, 2020 - The National Institutes of Health and the Foundation for the NIH (FNIH) are bringing together more than a dozen leading biopharmaceutical companies, the Health and Human Services Office of the Assistant Secretary for Preparedness and Response, the Centers for Disease Control and Prevention, the U.S.
Immunity from COVID-19 antibodies not certain, HIV co-discoverer cautions
April 14, 2020 - The race is on to develop and distribute antibody tests for the coronavirus, driven by the idea that these tests will inform individuals when they are immune to the virus and can return to their normal lives
Drug Evaluation during the Covid-19 Pandemic
April 14, 2020 - The search for a treatment for Covid-19 is testing our country’s ability to quickly develop, test, and deploy medications, presenting both opportunities and challenges to our drug-assessment apparatus
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)
April 13, 2020 - The pandemic of coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents an unprecedented challenge to identify effective drugs for prevention and treatment
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)
April 13, 2020 - The pandemic of coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents an unprecedented challenge to identify effective drugs for prevention and treatment
Trade set to plunge as COVID-19 pandemic upends global economy
April 13, 2020 - World trade is expected to fall by between 13% and 32% in 2020 as the COVID 19 pandemic disrupts normal economic activity and life around the world
Update on EU actions to support availability of medicines during COVID-19 pandemic
April 10, 2020 - The continued availability of medicines is one of the most important priorities for EU authorities that are adopting measures to mitigate possible disruptions to the supply of medicines caused by the ongoing COVID-19 pandemic
Compassionate Use of Remdesivir for Patients with Severe Covid-19
April 10, 2020 -O remdesivir, um pró-fármaco análogo de nucleotídeo que inibe a polimerase de RNA viral, demonstrou atividade in vitro contra SARS-CoV-2
COVID-19 and risks to the supply and quality of tests, drugs, and vaccines
April 09, 2020 - Emergency efforts are underway to find optimum medical products to prevent infection and diagnose and treat patients during the coronavirus disease 2019 (COVID-19) pandemic
Structure of Mpro from COVID-19 virus and discovery of its inhibitors
April 09, 2020 - A new coronavirus (CoV) identified as COVID-19 virus is the etiological agent responsible for the 2019-2020 viral pneumonia outbreak that commenced in Wuhan
Treatment options for COVID-19: The reality and challenges
April 04, 2020 - An outbreak related to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan, China in December 2019
Situação patentária de produtos passíveis para uso contra à Covid-19
09.04.2020 - Dando prosseguimento ao estudo sobre possíveis moléculas e produtos para tratamento e prevenção da COVID-19, após os estudos elaborados a partir das informações obtidas no estudo publicado pela American Chemical Society , a ABIFINA traz um levantamento das patentes correspondentes brasileiras de produtos já comercializados para prevenção e tratamento de outras doenças que possam ser utilizados para prevenção e tratamento de COVID-19
Global regulators stress need for robust evidence on COVID-19 treatments
April 09, 2020 - International regulators have published a report today highlighting their considerations on the development of potential COVID-19 therapeutics, clinical trials and compassionate use programmes
BMJ's Coronavirus (covid-19) Hub
April 09, 2020 -BMJ's covid-19 hub supports health professionals and researchers with practical guidance, online CPD courses, as well as the latest news, comment, and research from The BMJ.
Situação patentária de vacinas relacionadas à Covid-19
08.04.2020 - Dando prosseguimento ao estudo sobre possíveis moléculas para tratamento e prevenção da COVID-19, a partir das informações obtidas no estudo publicado pela American Chemical Society , a ABIFINA traz um levantamento das patentes correspondentes brasileiras de vacinas que possam ser utilizadas na pandemia de COVID-19
Global regulators discuss observational studies of real world data for COVID-19 medicines
April 07, 2020 - In a dedicated COVID-19 workshop, organised by the European Medicines Agency (EMA) under the umbrella of the International Coalition of Medicines Regulatory Authorities (ICMRA), international regulators discussed how data generated during clinical practice could complement evidence from clinical trials with potential therapeutics or vaccines against COVID-19
Atazanavir inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production
April 07, 2020 - Besides social isolation, identification of the suitable clinically approved drugs to be repurposed could lead to short-term action to reduce mortality
Open for outbreaks
April 07, 2020 - In the onslaught of the COVID-19 pandemic, the open sharing of materials, information and data is gaining increasing importance in biotech.
Coalition launched to accelerate research on the prevention and treatment of COVID-19 in low- and middle-income countries
April 03, 2020 - A group of scientists, physicians, funders, and policy makers from over 70 institutions from over 30 countries have launched an international coalition to respond to COVID-19 in resource-poor settings
EMA provides recommendations on compassionate use of remdesivir for COVID-19
April 03, 2020 - During an extraordinary virtual meeting held on 2 April 2020, EMA’s human medicines committee (CHMP) gave recommendations on how the investigational antiviral medicine remdesivir should be used for treating coronavirus disease (COVID-19) in compassionate use programmes in the European Union
International regulators discuss available knowledge supporting COVID-19 medicine development
April 03, 2020 - On 2 April, regulators from around the world joined the second workshop on COVID-19 organised by the European Medicines Agency (EMA) under the umbrella of the International Coalition of Medicines Regulatory Authorities (ICMRA)
Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS, or COVID‐19: initial assessment
April 02, 2020 - Several antiretroviral drugs are being considered the treatment of COVID‐19, the disease caused by a newly identified coronavirus, (SARS‐CoV‐2).
HHS accepts donations of medicine to Strategic National Stockpile as possible treatments for COVID-19 patients
April 02, 2020 - FDA issues emergency use authorization for donated hydroxychloroquine sulfate, chloroquine phosphate
Coronavirus disease (COVID-2019) R&D
April 02, 2020 - On 31 December 2019, WHO was informed of a cluster of cases of pneumonia of unknown cause detected in Wuhan City, Hubei Province of China
Optimizing the Trade-off Between Learning and Doing in a Pandemic
April 02, 2020 - The world is united regarding the goal of ending the coronavirus disease 2019 (COVID-19) pandemic but not the strategy to achieve that goal
COVID-19: combining antiviral and anti-inflammatory treatments
April 01, 2020 - Both coronavirus disease 2019 (COVID-19) and severe acute respiratory syndrome (SARS) are characterised by an overexuberant inflammatory response and, for SARS, viral load is not correlated with the worsening of symptoms
Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19
March 30, 2020 - The renin–angiotensin– aldosterone system (RAAS) is an elegant cascade of vasoactive peptides that orchestrate key processes in human physiology.
NOTA INFORMATIVA Nº 5/2020-DAF/SCTIE/MS
27.03.2020 - Uso da Cloroquina como terapia adjuvante no tratamento de formas graves do COVID-19
Use of antiviral drugs to reduce COVID-19 transmission
March 27, 2020 - As the coronavirus disease 2019 (COVID-19) spreads, efforts are being made to reduce transmission via standard public health interventions based on isolation of cases and tracing of contacts.
EMA advises continued use of medicines for hypertension, heart or kidney disease during COVID-19 pandemic
March 27, 2020 - EMA is aware of recent media reports and publications which question whether some medicines, for instance angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs, or sartan medicines), could worsen coronavirus disease (COVID-19)
Exportação de cloroquina e azitromicina: veja a RDC 352
March 27, 2020 - De acordo com a Resolução da Diretoria Colegiada 352, a exportação necessitará temporariamente de autorização prévia da Anvisa.
Situação patentária de moléculas e composições relacionadas à Covid-19
25.03.2020 - Diante da pandemia da COVID-19, e a partir das informações obtidas por um estudo publicado pela American Chemical Society , a ABIFINA fez um levantamento preliminar das patentes brasileiras correspondentes para as moléculas que estão sendo estudadas para prevenção e/ou tratamento da COVID-19.
Gilead Declines 'Rare Disease' Status For Experimental Coronavirus Drug
March 26, 2020 - In a surprising turnabout, drugmaker Gilead Sciences asked the Food and Drug administration on Wednesday to rescind orphan status for remdesivir, the company's experimental coronavirus treatment
India bans exports of drug touted by Trump as potential Covid-19 treatment
March 26, 2020 - Amendment in Export Policy of Hydroxychloroquine
Global regulatory workshop on COVID-19 vaccine development
March 25, 2020 - A virtual meeting, held under the umbrella of the International Coalition of Medicines Regulatory Authorities (ICMRA), convening experts from medicines regulatory authorities, the World Health Organisation (WHO) and the European Commission
Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)
March 25, 2020 - In vitro studies revealed that lopinavir/ritonavir and hydroxychloroquine have antiviral activity against Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
The Official Chinese Government Guide to Diagnosing and Treating the Novel Coronavirus
March 25, 2020 - You may not have heard of it. It’s now on version 7. You should read it.
Resources and Use of Approved Therapies for Treatment of n-CoViD-19 Disease
March 2020 - Therapies Approved by US FDA for Other Conditions
Insights from nanomedicine into chloroquine efficacy against COVID-19
March 23, 2020 - Chloroquine — an approved malaria drug — is known in nanomedicine research for the investigation of nanoparticle uptake in cells, and may have potential for the treatment of COVID-19
FDA and EMA Collaborate to Facilitate SARS-CoV-2 Vaccine Development
March 23, 2020 - Vaccines offer a way to build immunity to a disease-causing microorganism before one has ever been exposed to it. They have been highly effective in preventing a whole range of serious infectious diseases
The first study of a potential coronavirus vaccine will soon start recruiting healthy volunteers in Georgia at Emory University
Mar 23, 2020 - A pharmacist gives Jennifer Haller, left, the first shot in the first-stage safety study clinical trial of a potential vaccine for COVID-19, the disease caused by the new coronavirus, Monday, March 16, 2020, at the Kaiser Permanente Washington Health Research Institute in Seattle.
Genentech Announces FDA Approval of Clinical Trial for Actemra to Treat Hospitalized Patients With Severe COVID-19 Pneumonia
March 23, 2020 - Genentech will also provide 10,000 vials of Actemra to the U.S. Strategic National Stockpile. Current U.S. supply of Actemra for approved indications is not expected to be impacted
WHO launches global megatrial of the four most promising coronavirus treatments
Mar. 22, 2020 - Could any of these drugs hold the key to saving coronavirus disease 2019 (COVID-19) patients from serious harm or death? On Friday, the World Health Organization (WHO) announced a large global trial, called SOLIDARITY, to find out whether any can treat infections with the new coronavirus for the dangerous respiratory disease.
The pandemic pipeline
20 March 2020 - Companies are doing their best to accelerate experimental drugs and vaccines for COVID-19 through the pipeline. Each faces its own set of challenges, but all agree on the need for a radical rethink of the clinical development process for pandemics.
The pandemic pipeline
20 March 2020 - Companies are doing their best to accelerate experimental drugs and vaccines for COVID-19 through the pipeline. Each faces its own set of challenges, but all agree on the need for a radical rethink of the clinical development process for pandemics.
Chloroquine, Past and Present
20 March, 2020 - Derek Lowe's commentary on drug discovery and the pharma industry. An editorially independent blog from the publishers of Science Translational Medicine. All content is Derek’s own, and he does not in any way speak for his employer.
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
March 18, 2020 - No therapeutics have yet been proven effective for the treatment of severe illness caused by SARS-CoV-2
Sanofi, Regeneron test arthritis drug against COVID-19
March 18, 2020 - New study explores whether dampening IL-6 could address serious coronavirus infections
Chilean Chamber of Deputies approves resolution for compulsory licenses for patents relating to the coronavirus virus
March 17, 2020 - Today, with an overwhelming 127 votes in favor and 0 votes against, the Chilean Chamber of Deputies approved a strong resolution asking the Chilean Government to declare that there is justification for compulsory licenses for vaccines, drugs, diagnostics, devices, supplies, and other technologies useful for the surveillance, prevention, detection, diagnosis and treatment of people infected by the coronavirus virus in Chile.
Hydroxychloroquine would be effective, according to Professor Raoult of the IHU in Marseille, after a first limited test
March 17, 2020 - Professor Didier Raoult, director of the IHU in Marseille, presented the first results of the hydroxychloroquine clinical test carried out on 24 patients suffering from coronavirus.
Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus
16 March 2020 - Estimation of the prevalence and contagiousness of undocumented novel coronavirus (SARS-CoV2) infections is critical for understanding the overall prevalence and pandemic potential of this disease.
Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases
March 12, 2020 - Since the outbreak of the novel coronavirus disease COVID-19, caused by the SARS-CoV-2 virus, this disease has spread rapidly around the globe. Considering the potential threat of a pandemic, scientists and physicians have been racing to understand this new virus and the pathophysiology of this disease to uncover possible treatment regimens and discover effective therapeutic agents and vaccine
